Table 2.
Examples of active and completed trials based on varied formats of CD40 stimulation. Information from ClinicalTrials.gov
| TRIAL NUMBER | AGENT | DISEASE | STATUS |
|---|---|---|---|
| NCT04491084 | FLT3L; anti-CD40; stereotactic radiation | NSCLC | Recruiting |
| NCT01433172 | GM.CD40L transfected K562 cellular vaccine with CCL21 | Lung adenocarcinoma | Completed |
| NCT04635995 | Agonistic anti-CD40+/‒ anti-PD1+/‒ anti-CD137 | Advanced/metastatic malignancies | Recruiting |
| NCT02482168 | Agonistic anti-CD40 | Varied solid tumors | Completed |
| NCT00058799 | CD40L and IL-2 transfected fibroblasts | Leukemia | Completed |
| NCT04364230 | Agonistic anti-CD40 + peptides+polyICLC | Melanoma | Recruiting |
| NCT04406623 | SIRPα-Fc-CD40L | Ovarian | Recruiting |
| NCT01561911 | Agonistic Anti-CD40 | Advanced malignancies | Completed |
| NCT01103635 | Anti-CD40 + anti-CTLA4 | Metastatic melanoma | Completed |
| NCT00020540 | Flt3L and soluble CD40L | Metastatic melanoma or renal cancer | Completed |
| NCT03719430 | Anti-CD40 and doxorubicin | Advanced sarcoma | Recruiting |
| NCT03329950 | Anti-CD40+/‒ Ftl3L or anti-PD1 or chemotherapy | Varied malignancies | Recruiting |
| NCT03852511 | Oncolytic adenovirus expressing anti-CD40 ab | Metastatic cancer and epithelial tumors | Recruiting |